Article

Laboratoires Thea acquires insert from Carl Zeiss Meditec

Laboratoires Thea has acquired from Carl Zeiss Meditec a mydriatic ophthalmic insert (Mydriasert) indicated for dilated fundus examination or cataract surgery.

Clermont-Ferrand, France-Laboratoires Thea has acquired from Carl Zeiss Meditec a mydriatic ophthalmic insert (Mydriasert) indicated for dilated fundus examination or cataract surgery.

The agreement includes the acquisition of the production site of the insert in La Rochelle, France, along with relevant staff.

“This acquisition represents a significant addition to our product range and is completely in line with our strategy to become a leading provider of ophthalmic products,” said Jean-Frederic Chibret, Laboratoires Thea chief operating officer.

This device, shaped like an oblong tablet, is applied beneath the eyelid and disperses phenylephrine hydrochloride and tropicamide. The alpha-sympathomimetic activity of phenylephrine induces an increase in pupil diameter, and the anti-cholinergic activity of tropicamide prevents the iris from contracting, according to the company.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.